Serum IL-21 levels correlated with the frequency of IL-21-producing CD4+ T cells in the BM of newly diagnosed patients with AML and could therefore be used clinically as a surrogate biomarker to address the stemness signature of a patient’s AML blasts and to predict outcome. The gene discussed is CD4; the disease is acute myeloid leukemia.